

Review Form 1.7

Journal Name:	International Journal of Medical and Pharmaceutical Case Reports
Manuscript Number:	Ms_IJMPCR_115087
Title of the Manuscript:	Nightmares caused by nevirapine during chemoradiotherapy for carcinoma tongue
Type of the Article	Case Report

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p>Compulsory REVISION comments</p> <p>1. Is the manuscript important for scientific community? (Please write few sentences on this manuscript)</p> <p>2. Is the title of the article suitable? (If not please suggest an alternative title)</p> <p>3. Is the abstract of the article comprehensive?</p> <p>4. Are subsections and structure of the manuscript appropriate?</p> <p>5. Do you think the manuscript is scientifically correct?</p> <p>6. Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form.</p> <p>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</p>	<p>1. it may be interesting</p> <p>2. I propose "Nightmares associated to nevirapine during chemoradiotherapy for carcinoma tongue"</p> <p>3. ok</p> <p>4. OK</p> <p>5. it is an hypothesis about a possible interaction between nevirapine and cisplatin</p> <p>6. ok</p>	
<p>Minor REVISION comments</p> <p>1. Is language/English quality of the article suitable for scholarly communications?</p>	<p>It may be enhanced</p>	
<p>Optional/General comments</p>	<ul style="list-style-type: none"> - Explain more the mechanism of nightmare with nevirapine and its usual presentation (delay, outcome..) - Accentuate that it is your hypothesis that the nightmare may be due to an interaction with CYP2B6 inhibition by cisplatin as it is not reported in literature. In fact, in the reference 4, it is stipulated that "The cisplatin, although it is able to inhibit partly the activities of CYP enzymes (to 75% of activity of CYP2C9, at 400 mmol/l), is not expected to elicit a clinically relevant interaction because of low plasma levels of this drug" 	

[Review Form 1.7](#)

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Imen Aouinti
Department, University & Country	Centre National Chalbi Belkahia de Pharmacovigilance, Tunisia